All In MedTech

Device Trial Radar · NCT03528057

Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy

Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy

Last checked: Nov 20, 2026Latest source record: Jul 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Apr 18, 2018

Primary completion

May 2019

Study completion Jun 2020

Sponsor

Lead sponsor
Northwestern UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 17, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate whether Hemostatic Agents (HA) make a significant clinical difference in patient outcomes when used for Robotic-Assisted Laparoscopic Partial Nephrectomy (RALPN). The result of this trial will determine whether HAs are necessary for use during RALPN or if they can be omitted from the surgical tools available during this procedure. This study has a direct clinical implication on a patient's outcomes following RALPN, specifically whether patients will have better, worse, or unchanged outcomes with RALPN if HAs are used.

Conditions

  • Robotic-Assisted Laparoscopic Partial Nephrectomy
  • Hemostatic Agents
  • Renal Malignant Tumor

Interventions

  • HemostatDevice

    Hemostatic agents, if used at all during surgery, will be applied laparoscopically into the tumor bed to stop bleeding. The type of hemostat will be decided by the surgeon according to the anatomy of the tumor bed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change in hemoglobinTime frame: Morning after surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Northwestern Memorial Hospital

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.